Scott Glaser

Oncologist | Chief of #Brachytherapy and Gyn #radonc at
@cityofhope | Views are my own

[Colton Ladbury, MD @ColtonLadbury]

A little late but could not be more appreciative of my team @cityofhopeoc and their efforts in getting our inpatient gyn interstitial program off the ground. We have delivered our first treatment at Lennar, a critical step in being a full service brachy program for OC patients!

[City of Hope - Department of Radiation Oncology @COH_RadOnc]

We are thrilled to welcome two outstanding resident physicians to our team from 2027-2031. Happy match day! @cityofhope @ASTRO_org @TheNRMP #Match2026 #radonc

[NEJM @NEJM]

Advances in the planning and delivery of radiation treatments have come from efforts to simultaneously reduce negative effects in normal tissues and enhance tumor control (seen in figure). Learn more: https://t.co/EP9XJ6c8CF

[City of Hope - Department of Radiation Oncology @COH_RadOnc]

Both our chief residents (@AriKassardjian1 and @Nick_Eustace) represented @cityofhope at #SABCS2025 presenting posters under the excellent mentorship of Jose Bazan MD. Excellent work!

[Sushil @Sushilberiwal]

Demo video from assembly to insertion for Aarhus applicator for cervical cancer
https://t.co/oGZc6Vx2Wv @AmericanBrachy @ACRORadOnc @ACRORadOnc @KamravaMD @MattHarkenrider @DocGlaser

[Scott Glaser @DocGlaser]

Welcome @adapthyun !

[Terry Williams @TeWilliamsMD]

We’re thrilled to welcome @adapthyun to @COH_RadOnc! Dr. Hyun Kim is an internationally-recognized thought leader in GI cancer, adaptive radiation therapy & radiopharmaceuticals, and will lead our GI RadOnc & #theranostics programs. #radonc @cityofhope @NRGonc @ASTRO_org

[NRG Oncology @NRGonc]

On Monday, Sept 29th, we announced the activation of NRG-GY037, a pivotal Phase III randomized trial for patients with high-risk, locally advanced cervical cancer. PI: Jyoti Mayadev, MD @UCSDHealth Read more: https://t.co/cZoM4WZsL3

[Scott Glaser @DocGlaser]

Let’s talk #radonc during @ASTRO_org #ASTRO25. Join me and @ClaytonLadbury for a Meet & Greet session at the @cityofhope booth today!

[Scott Glaser @DocGlaser]

Excited to be a social ambassador for @cityofhope during @ASTRO_org #ASTRO25. Catch my updates from the conference floor on X and LinkedIn!

[Scott Glaser @DocGlaser]

Interested in #radonc? Join us for an open house September 24!

[City of Hope - Department of Radiation Oncology @COH_RadOnc]

Hosting a Virtual Open House on 9/24 from 3-5 PM for medical student applicants interested in #radonc @cityofhope @DrAryaAmini @TeWilliamsMD @ColtonLadbury @DocGlaser

[Sushil @Sushilberiwal]

First Hybrid brachytherapy with Aarhus applicator in chicoutimi hospital, Quebec @AmericanBrachy on brachy awareness day @KamravaMD @DocGlaser @AndrewKellerMD

[Scott Glaser @DocGlaser]

Congrats!

[American Brachy @AmericanBrachy]

Join us in celebrating the remarkable achievements of our 2025 #ABSFellows. These exceptional individuals are the epitome of brilliance, passion, and commitment to making a positive impact in the field of #brachytherapy. @TimShowalter1 @SanghviMd @UCSDRadMed @MedicineUVA

[Scott Glaser @DocGlaser]

@DrSpratticus Interesting brachy had less urinary toxicity than EBRT. I typically counsel the reverse. Selection bias?

[Pierre Blanchard, MD @PBlanchardMD]

Reassuring toxicity data from PCS IX trial after hypofractionated (5*5 Gy) pelvic & prostate #radiotherapy priori to #brachytherapy boost for #prostatecancer.

#ESTRO25

[Pierre Blanchard, MD @PBlanchardMD]

STORM-PEACE V trial reported by @ZilliThomas #ESTRO25

Pelvic ENI superior to MDT for pelvic relapses after local Tx for #prostate cancer (6mo ADT each)

Improves
Biochemical PFS
Locoregional PFS
MFS
ADT free survival
Tox NS

ENI clear SOC

Online @TheLancetOncol

Cc @piet_ost

[Sushil @Sushilberiwal]

Isotoxic FLAME shows 15% BCR difference with 10 years follow up with significant difference in local and regional recurrence #ESTRO2025 @AmarUKishan

[Giulia Marvaso @GiuliaMarvaso84]

Elective para-aortic RT + 24 months ADT shows promising results in pN1 prostate cancer! In the PART trial (n=96), 5y clinical RFS reached 91% in the adjuvant setting vs 63% salvage (p=0.029) with acceptable toxicity. Early intervention matters. #ESTRO2025 #RadOnc #ProstateCancer

[Sushil @Sushilberiwal]

Best #ESTRO2025 abstract for EMBRACE2 showing excellent locoregional control and significantly reduced morbidity compared to embrace 1 with tighter dose constraints with higher use of hybrid applicator ( new standard ) @KamravaMD @DocGlaser @AndrewKellerMD @AmericanBrachy

[Ane Appelt @cancerphysicist]

PLATO ACT 4 results for dose de-escalation in early-stage anal cancer are out! Prof Sebag-Montefiore presents on the plenary stage at #ESTRO24

3-year locoregional failure 16.4% for standard dose IMRT vs 12.4% reduced dose IMRT

Reduced dose IMRT is safe & effective!
#radonc

[Sushil @Sushilberiwal]

Danish data with longer follow up shows no difference in lymphedema or LRR with RNI hypofractionation @Icro_Meattini @ErinGillespieMD @DocGlaser @AndrewKellerMD #estro2025